Drug Profile
Ezetimibe/rosuvastatin - Alvogen Korea
Alternative Names: DP R207; Rosuvastatin/ezetimibe - Alvogen KoreaLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator DreamPharma Corporation
- Developer Alvogen Korea
- Class Antihyperlipidaemics; Azetidines; Fluorobenzenes; Phenols; Propanols; Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors; NPC1L1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypercholesterolaemia
Most Recent Events
- 06 Feb 2019 Chemical structure information added
- 01 Mar 2015 DreamPharma Corporation completes the phase III ROSE trial in Hypercholesterolaemia in South Korea (NCT02445352)
- 01 Jul 2014 Phase-III clinical trials in Hypercholesterolaemia in South Korea (PO) (NCT02445352)